Beta-Blockers in Takotsubo Syndrome Study

Launched by SPANISH SOCIETY OF CARDIOLOGY · Jul 16, 2024

Keywords

ClinConnect Summary

The Beta-Blockers in Takotsubo Syndrome Study (β-Tako trial) is a research project looking into how effective beta-blockers, a type of medication often used for heart-related conditions, are for patients diagnosed with Takotsubo Cardiomyopathy. This condition can cause the heart to temporarily weaken, often triggered by stress. In this trial, 200 patients will be randomly assigned to receive either beta-blockers or no treatment for a period of time. The main goal is to see how well the heart is functioning after one week using a heart imaging test called echocardiography. Researchers will also monitor participants for serious health events over the course of a year.

To be eligible for this trial, patients must be diagnosed with Takotsubo syndrome and provide their consent to participate. They should not have significant coronary artery disease and must be experiencing their symptoms within the last 48 hours. Unfortunately, certain individuals, such as those with severe heart issues or who are pregnant, cannot participate. If you or a loved one is interested in this study, it could provide valuable insights into how to better treat this unique heart condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent.
• • Diagnosis of TTS with exclusion of significant coronary artery disease (CAD) by invasive coronary angiography
• Exclusion Criteria:
• • Patients diagnosed of TTS \> 48 hours before.
• • Persistent ccardiogenic shock or severe hemodynamic instability
• • Persistent severe (\>30 mmHg) intraventricular gradient
• • Previous diagnosis of severe valvular or ventricular disease or prior myocardial infarction secondary to atherosclerotic CAD
• • Patients already receiving treatment with betablockers (\*)
• • Absolute contraindication/indication for beta-blockers (\*\*)
• • Poor echocardiographic window
• • Pregnant or breastfeeding women.
• • Participation in another clinical trial.
• • (\*) Betablockers at a therapeutic dose at the time of symptom´s onset. (\*\*) Close ECG monitoring required in patients with hypotension, bradycardia or cQT interval prolongation